ATE497949T1 - Tubulininhibitoren - Google Patents

Tubulininhibitoren

Info

Publication number
ATE497949T1
ATE497949T1 AT04801111T AT04801111T ATE497949T1 AT E497949 T1 ATE497949 T1 AT E497949T1 AT 04801111 T AT04801111 T AT 04801111T AT 04801111 T AT04801111 T AT 04801111T AT E497949 T1 ATE497949 T1 AT E497949T1
Authority
AT
Austria
Prior art keywords
tubulin inhibitors
diastereomers
solvates
hydrates
salts
Prior art date
Application number
AT04801111T
Other languages
English (en)
Inventor
Christopher Burns
Andrew Wilks
Michael Harte
Harrison Sikanyika
Emmanuelle Fantino
Colette Sims
Original Assignee
Ym Biosciences Australia Pty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003906680A external-priority patent/AU2003906680A0/en
Application filed by Ym Biosciences Australia Pty filed Critical Ym Biosciences Australia Pty
Application granted granted Critical
Publication of ATE497949T1 publication Critical patent/ATE497949T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT04801111T 2003-12-03 2004-12-03 Tubulininhibitoren ATE497949T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003906680A AU2003906680A0 (en) 2003-12-03 Tubulin Inhibitors
PCT/AU2004/001689 WO2005054199A1 (en) 2003-12-03 2004-12-03 Tubulin inhibitors

Publications (1)

Publication Number Publication Date
ATE497949T1 true ATE497949T1 (de) 2011-02-15

Family

ID=34637692

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04801111T ATE497949T1 (de) 2003-12-03 2004-12-03 Tubulininhibitoren

Country Status (20)

Country Link
US (5) US7981900B2 (de)
EP (2) EP1689715B1 (de)
JP (2) JP4772690B2 (de)
KR (2) KR101206843B1 (de)
CN (2) CN1890218B (de)
AT (1) ATE497949T1 (de)
AU (1) AU2004294354B2 (de)
BR (1) BRPI0417354A (de)
CA (2) CA2545422C (de)
CY (1) CY1111410T1 (de)
DE (1) DE602004031357D1 (de)
DK (1) DK1689715T3 (de)
ES (2) ES2528302T3 (de)
IL (1) IL175576A (de)
NZ (1) NZ546057A (de)
PL (1) PL1689715T3 (de)
PT (2) PT1689715E (de)
SI (1) SI1689715T1 (de)
WO (1) WO2005054199A1 (de)
ZA (1) ZA200602664B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002953255A0 (en) * 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
SG150534A1 (en) 2003-11-20 2009-03-30 Janssen Pharmaceutica Nv 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp- ribose) polymerase inhibitors
SG150533A1 (en) 2003-11-20 2009-03-30 Janssen Pharmaceutica Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
EP1689715B1 (de) * 2003-12-03 2011-02-09 YM BioSciences Australia Pty Ltd Tubulininhibitoren
KR101211950B1 (ko) 2004-06-30 2012-12-13 얀센 파마슈티카 엔.브이. Ｐａｒｐ 저해제로서의 프탈아진 유도체
EA011552B1 (ru) 2004-06-30 2009-04-28 Янссен Фармацевтика Н.В. Производные хиназолиндиона в качестве ингибиторов parp
UA85593C2 (uk) 2004-06-30 2009-02-10 Янссен Фармацевтика Н.В. Похідні хіназолінону як інгібітори parp
EP1789393A2 (de) * 2004-07-30 2007-05-30 GPC Biotech AG Pyridinylamine
US20090281119A1 (en) * 2005-06-15 2009-11-12 Cytopia Research Pty Ltd. Acid addition salts of n-ethyi-n'-[2-methoxy-4-(5-methyi-4-pryimidin-2-yl)phenyl]urea and uses thereof
JP5252404B2 (ja) * 2006-08-16 2013-07-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラジン化合物、その使用及び調製方法
DE102006049618A1 (de) * 2006-10-20 2008-05-08 Tschesche, Harald, Prof. Dr. Triazine und Ihre Verwendung als Metalloproteinase-Inhibitoren
PL2848610T3 (pl) * 2006-11-15 2018-01-31 Ym Biosciences Australia Pty Inhibitory aktywności kinazy
AU2013273769B2 (en) * 2006-11-15 2016-05-12 Ym Biosciences Australia Pty Ltd Inhibitors of Kinase Activity
ATE542799T1 (de) 2007-03-08 2012-02-15 Janssen Pharmaceutica Nv Chinolinonderivate als parp und tank-inhibitoren
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
JPWO2009096198A1 (ja) * 2008-02-01 2011-05-26 一般社団法人ファルマＩｐ 新規ビアリール誘導体
WO2009118382A1 (en) 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
WO2009118384A1 (en) 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
MX2010012080A (es) * 2008-05-05 2011-04-11 Univ Winthrop Hospital Metodo para mejorar el perfil de riesgo cardiovascular de los inhibidores de cox.
LT2300013T (lt) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Fosforo dariniai kaip kinazių inhibitoriai
US8507491B2 (en) 2008-08-25 2013-08-13 Irm Llc Compounds and compositions as hedgehog pathway inhibitors
WO2010046780A2 (en) * 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
US8541424B2 (en) * 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
EP2367823A1 (de) 2008-12-23 2011-09-28 Abbott Laboratories Antivirale verbindungen
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
EP2499152B1 (de) 2009-11-12 2016-06-29 TUBE Pharmaceuticals GmbH Tubulin inhibitoren
EP2322537A1 (de) 2009-11-12 2011-05-18 R & D Biopharmaceuticals Gmbh Tubulinhemmer
CN103608026B (zh) * 2011-06-13 2016-08-24 伊利诺伊大学受托管理委员会 肽组合物和用于治疗肺损伤、哮喘、过敏反应、血管性水肿、全身性血管通透综合征和鼻塞的方法
PT2814820T (pt) * 2012-02-17 2016-10-25 Medicines For Malaria Venture Mmv Novos agentes antimaláricos
CN102826985B (zh) * 2012-09-18 2015-08-19 厦门大学 一种1-(3,4,5-三羟基)苯基-1-烷基酮的制备方法
CN105142624A (zh) 2013-01-10 2015-12-09 普尔莫凯恩股份有限公司 非选择性激酶抑制剂
EP2988738A4 (de) * 2013-01-10 2016-11-09 Pulmokine Inc Therapeutische anwendungsgebiete von kinasehemmern
CN111743901B (zh) 2013-10-11 2023-09-12 普尔莫凯恩股份有限公司 喷雾干燥制剂
WO2016167795A1 (en) * 2015-04-17 2016-10-20 Southern Research Institute Treatment of hepatitis b viral
CN106167482A (zh) * 2015-05-19 2016-11-30 重庆大学 一种抑制前列腺癌生长的化合物及其应用
CN107304202A (zh) * 2016-04-20 2017-10-31 苏州苏领生物医药有限公司 五元杂环类化合物及其制备方法、药物组合物和用途
WO2017181974A1 (zh) * 2016-04-20 2017-10-26 苏州苏领生物医药有限公司 五元杂环类化合物及其制备方法、药物组合物和用途
CN106565685B (zh) * 2016-10-11 2019-03-01 深圳海王医药科技研究院有限公司 微管蛋白抑制剂
JP2020500183A (ja) 2016-10-27 2020-01-09 プルモキネ、インコーポレイテッド 肺高血圧症の治療のための併用療法
EP3720436A4 (de) * 2017-12-06 2021-06-02 Lin Bioscience, Pty Ltd. Tubulinhemmer
CN111741944A (zh) * 2018-02-01 2020-10-02 悉尼大学 抗癌化合物
CN108658963A (zh) * 2018-06-20 2018-10-16 桑文军 一种作用于微管蛋白的抗肿瘤药物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE82928C (de) 1893-06-18 1895-10-01
FR352807A (fr) 1905-03-28 1905-08-22 Julius Schroeder Perfectionnements apportés aux boites à fumée des chaudières à tubes bouilleurs et aux brosses de nettoyage
GB253816A (en) 1925-12-29 1926-06-24 Spencer Bonecourt Ltd Improvements relating to the cleaning of the fire-tubes of a boiler
US3354490A (en) 1964-06-15 1967-11-28 Power Tube Inc Boiler tube cleaning apparatus
CH593266A5 (de) * 1973-09-20 1977-11-30 Delalande Sa
US4367790A (en) 1980-12-16 1983-01-11 Draeger Walter A Multiple tube cleaning apparatus
JPS61228296A (ja) 1985-03-30 1986-10-11 Takao Sakamoto 熱交換器における伝熱管の内面洗浄方法
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
AT405973B (de) 1998-06-26 2000-01-25 Hackl Hubert Reinigungsvorrichtung für wärmetauscherzüge
DE19853278A1 (de) * 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
JP2000180093A (ja) 1998-12-15 2000-06-30 Toshiba Plant Kensetsu Co Ltd 熱交換器の管内清掃・探傷検査装置、及び管内清掃・探傷検査方法
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
BR0113148A (pt) * 2000-08-08 2003-07-08 Ortho Mcneil Pharm Inc Composições de 2-piridinamina e métodos relacionados
CN100506801C (zh) * 2000-09-06 2009-07-01 诺华疫苗和诊断公司 糖元合成酶激酶3的抑制剂
AU2001292670A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
EP1351691A4 (de) * 2000-12-12 2005-06-22 Cytovia Inc Substituierte 2-aryl-4-arylaminopyrimidine und ihre analoge als aktivatoren von caspasen und apoptoseinduktoren, sowie deren verwendung
CA2436487A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
EP1373257B9 (de) * 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Hemmer von c-jun-terminal kinase (jnk) und andere protein kinase
WO2003026661A1 (fr) 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
AU2002342051B2 (en) * 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
AU2003232919B2 (en) * 2002-05-23 2009-03-05 Ym Biosciences Australia Pty Ltd Protein kinase inhibitors
GB2392154B (en) 2002-05-23 2005-01-19 Cytopia Pty Ltd Protein Kinase Inhibitors
WO2004000318A2 (en) * 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CA2506772A1 (en) * 2002-11-01 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
WO2004041810A1 (en) * 2002-11-05 2004-05-21 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
PL376993A1 (pl) * 2002-11-11 2006-01-23 Bayer Healthcare Ag Pochodne fenylo- lub heteroarylo-aminoalkanów jako antagoniści receptora IP
AU2002953255A0 (en) 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
CA2530389A1 (en) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
BRPI0412347A (pt) * 2003-07-30 2006-09-05 Cyclacel Ltd 2-aminofenil-4-fenilpiridinas como inibidores de quinase
EP1689715B1 (de) * 2003-12-03 2011-02-09 YM BioSciences Australia Pty Ltd Tubulininhibitoren
US20090281119A1 (en) 2005-06-15 2009-11-12 Cytopia Research Pty Ltd. Acid addition salts of n-ethyi-n'-[2-methoxy-4-(5-methyi-4-pryimidin-2-yl)phenyl]urea and uses thereof
JP5539734B2 (ja) 2007-01-31 2014-07-02 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド チオピリミジンベースの化合物およびその使用

Also Published As

Publication number Publication date
JP5318126B2 (ja) 2013-10-16
KR20060123246A (ko) 2006-12-01
CA2857067C (en) 2016-11-22
US8394806B2 (en) 2013-03-12
US9732046B2 (en) 2017-08-15
BRPI0417354A (pt) 2007-03-13
CY1111410T1 (el) 2015-08-05
US20080194583A1 (en) 2008-08-14
CN1890218A (zh) 2007-01-03
PT1689715E (pt) 2011-05-16
ZA200602664B (en) 2007-06-27
AU2004294354B2 (en) 2009-02-19
CA2545422A1 (en) 2005-06-16
PL1689715T3 (pl) 2011-07-29
EP2277865A1 (de) 2011-01-26
JP2011093930A (ja) 2011-05-12
EP1689715B1 (de) 2011-02-09
EP1689715A4 (de) 2008-01-23
US20110269760A1 (en) 2011-11-03
ES2360703T3 (es) 2011-06-08
IL175576A (en) 2012-03-29
CN102127056A (zh) 2011-07-20
US20140221396A1 (en) 2014-08-07
US9139560B2 (en) 2015-09-22
DE602004031357D1 (de) 2011-03-24
KR101206843B1 (ko) 2012-11-30
CA2857067A1 (en) 2005-06-16
EP2277865B1 (de) 2014-11-12
ES2528302T3 (es) 2015-02-06
JP4772690B2 (ja) 2011-09-14
NZ546057A (en) 2010-04-30
US20160031835A1 (en) 2016-02-04
IL175576A0 (en) 2006-09-05
US7981900B2 (en) 2011-07-19
CN102127056B (zh) 2013-08-21
AU2004294354A1 (en) 2005-06-16
KR101260717B1 (ko) 2013-05-09
JP2007513093A (ja) 2007-05-24
US20130274263A1 (en) 2013-10-17
DK1689715T3 (da) 2011-05-23
WO2005054199A1 (en) 2005-06-16
EP1689715A1 (de) 2006-08-16
SI1689715T1 (sl) 2011-07-29
PT2277865E (pt) 2015-02-05
CN1890218B (zh) 2011-08-03
KR20120008078A (ko) 2012-01-25
CA2545422C (en) 2015-06-02

Similar Documents

Publication Publication Date Title
DK1689715T3 (da) Tubulininhibitorer
ATE377004T1 (de) Proteinkinaseinhibitoren
DE60331187D1 (de) Kinaseinhibitoren
PL378555A1 (pl) Sulfonoamido-podstawione pochodne ksantyny do stosowania jako inhibitory PEPCK
RS92004A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TW200510441A (en) Novel compounds
CY1112780T1 (el) Νεα σουλφονυλοπυρρολια ως αναστολεις της ηdac
DK1836201T4 (da) Pyrrolidininhibitorer af IAP.
CY1114284T1 (el) Σουλφονυλοπυρρολες ως hdac αναστολεις
MXPA02012054A (es) Compuestos de dicetopiracina tetraciclica como inhibidores de la fosfodiesterasa v.
TW200508199A (en) Novel compound
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
EA200501900A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
AR048948A1 (es) Una composicion farmaceutica antimicobacteriana
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
GB0403148D0 (en) Chemical compounds
MXPA05006957A (es) Nuevos derivados de fosforamida.
TW200420713A (en) Liquid-crystalline media comprising polymers
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы
EA200600456A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200601086A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
DK1637141T3 (da) Stabiliseret proteasesammensætning omfattende en serinprotease, morpholinderivater og reversible inhibitorer af serinproteasen
ATE349452T1 (de) Prodrug eines beta-lactamase-inhibitors
CY1105789T1 (el) Νεα μεθοδος για τη συνθεση πepιντοπριλ και των φαρμακευτικως αποδεκτων αλατων αυτου

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1689715

Country of ref document: EP